Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Announces Agreement to Acquire LipoScience

Acquisition Price of $5.25 Per Share in All Cash Transaction NMR LipoProfile test expands LabCorp’s offering of personalized diagnostic tests BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 25, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) and LipoScience, Inc.

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of September 12, 2014 to March 11, 2015 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp’s Enlighten Health Launches Innovative Genomics Initiative

Enlighten Health Genomics Aims to Make Genetic Profiles a Routine Part of Clinical Decisions BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 4, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ; NYSE: LH) announced today the launch of Enlighten Health Genomics, a new business that builds on

LabCorp Announces the Availability of InformaSeqSM Non-Invasive Prenatal Test

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 19, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of the informaSeq Prenatal Test. The informaSeq Prenatal Test is an advanced, non-invasive, next-generation prenatal screening assay that can

Laboratory Corporation of America® Holdings Announces 2014 Second Quarter Results and Increases 2014 EPS Guidance

Sales of $1.52 billion Diluted EPS of $1.64 ; Adjusted EPS of $1.84 Operating Cash Flow of $207 million ; Free Cash Flow of $159 million 2014 Adjusted EPS guidance raised to $6.50 - $6.75 BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 18, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® )

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 1, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Announces the Availability of Luminex xTAG® CYP2D6 Genotype Assay

BURLINGTON, N.C. --(BUSINESS WIRE)--May 19, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of the xTAG ® CYP2D6 Kit v3 from Luminex Corporation (NASDAQ: LMNX). The xTAG CYP2D6 Kit v3 is an FDA cleared qualitative genotyping assay that

LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--May 8, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV.

LabCorp to Webcast Its Annual Meeting of Stockholders

BURLINGTON, N.C. --(BUSINESS WIRE)--May 5, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that its Annual Meeting of Stockholders will be webcast live beginning May 14, 2014 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com .